SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and MannKind Corporation

SG&A Trends: BioMarin vs. MannKind Over a Decade

__timestampBioMarin Pharmaceutical Inc.MannKind Corporation
Wednesday, January 1, 201430215600079383000
Thursday, January 1, 2015402271000108402000
Friday, January 1, 201647659300046928000
Sunday, January 1, 201755433600074959000
Monday, January 1, 201860435300079716000
Tuesday, January 1, 201968092400074669000
Wednesday, January 1, 202073766900059040000
Friday, January 1, 202175937500077417000
Saturday, January 1, 202285400900091473000
Sunday, January 1, 202393730000094314000
Monday, January 1, 20241009025000
Loading chart...

Unleashing insights

SG&A Efficiency: A Tale of Two Biopharma Giants

In the competitive world of biopharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, BioMarin Pharmaceutical Inc. and MannKind Corporation have demonstrated contrasting approaches to SG&A efficiency.

From 2014 to 2023, BioMarin's SG&A expenses surged by over 200%, reflecting its aggressive expansion strategy. In contrast, MannKind's expenses grew by a modest 19%, indicating a more conservative approach. By 2023, BioMarin's SG&A expenses were nearly 10 times higher than MannKind's, highlighting its significant investment in administrative and sales functions.

This divergence underscores the strategic choices each company has made in navigating the biopharma landscape. While BioMarin focuses on scaling operations, MannKind opts for a leaner model. Investors and industry analysts should consider these trends when evaluating the long-term sustainability and growth potential of these companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025